Biotech blockbuster forecasts to 2008

Datamonitor analysis recognises 18 biological brands that are expected to drive sales within the biopharma sector. The group includes 12 recombinant DNA proteins and six antibodies which are forecast to generate sales of US$29.0bn and US$13.2bn by 2008, respectively. Haematology, oncology and AIID (...

Full description

Saved in:
Bibliographic Details
Published in:Journal of commercial biotechnology 2004-10, Vol.11 (1), p.80-86
Main Authors: Pavlou, Alex K, Belsey, Mark
Format: Article
Language:English
Subjects:
Arthritis
Biotechnology
Biotechnology industry
Brands
Business forecasts
Chemotherapy
Diabetes
Franchises
Growth rate
Hematology
Infectious diseases
Inflammation
Marketing
Monoclonal antibodies
Oncology
Pharmaceuticals
Proteins
Sales
Statistical data
Success
Trends
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Datamonitor analysis recognises 18 biological brands that are expected to drive sales within the biopharma sector. The group includes 12 recombinant DNA proteins and six antibodies which are forecast to generate sales of US$29.0bn and US$13.2bn by 2008, respectively. Haematology, oncology and AIID (arthritis, inflammation and immune disorders) will drive blockbuster sales, reaching US$11.2bn, US$9.7bn and US$8.3bn by 2008, respectively. [PUBLICATION ABSTRACT]
ISSN:1462-8732
1478-565X
DOI:10.1057/palgrave.jcb.3040104